Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.47 |
| ▸ | BRAF | P15056 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185779 | 0.86 | RAF1 (0.58) | RAF1KDRBRAFHDAC1HDAC3 | |
| SCHEMBL257963 | 0.84 | RAF1 (0.59) | RAF1KDRBRAFMEN1KMT2A | |
| SCHEMBL938402 | 0.82 | RAF1 (0.58) | RAF1KDRBRAFMEN1KMT2A | |
| SCHEMBL4172684 | 0.79 | RAF1 (0.48) | RAF1KDRMEN1KMT2ANPC1 | |
| SCHEMBL12719565 | 0.79 | MEN1 (0.54) | KDRMEN1KMT2AIGF1RCSF1R | |
| SCHEMBL12749714 | 0.78 | MEN1 (0.47) | RAF1KDRMEN1KMT2AIGF1R | |
| SCHEMBL4173358 | 0.78 | RAF1 (0.52) | RAF1KDRMEN1KMT2AIGF1R | |
| SCHEMBL4185669 | 0.77 | BRAF (0.39) | RAF1KDRBRAFHDAC1HDAC3 | |
| SCHEMBL261957 | 0.77 | MAPT (0.49) | HDAC6MEN1KMT2ANPC1IGF1R | |
| SCHEMBL4181174 | 0.76 | RET (0.56) | RAF1KDRBRAFMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379507-B1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-08-17 | — | — | EP | claimed |
| JP-4359817-B2 | — | — | 2009-11-11 | — | — | JP | claimed |
| JP-2004537511-A | — | — | 2004-12-16 | — | — | JP | claimed |
| EP-1379507-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2004-01-14 | — | — | EP | claimed |
| WO-2002085859-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | BAYER CORPORATION | 2002-05-30 | — | — | US | claimed |
| US-7928239-B2 | Anticarcinogenic agents | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928239-B2 | Anticarcinogenic agents | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | MAPK1, MAP3K1, MAPK3 | RAF1 246/4885KDR 1661/4885BRAF 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.